NET

Thinking about trading options or stock in Cloudflare, Walt Disney, Ford Motor, Synopsys, or Marathon Digital?

Retrieved on: 
Friday, February 9, 2024
NET, SNPS, DIS, Report, Retail

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NET, DIS, F, SNPS, and MARA.

Key Points: 
  • NEW YORK, Feb. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NET, DIS, F, SNPS, and MARA.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report – Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Levi & Korsinsky, LLP Announces a Proposed Settlement in the Corcept Therapeutics Incorporated Securities Litigation

Retrieved on: 
Monday, February 5, 2024
Hearing, Prejudice, Tax, Person, Allocation, ALL, Claim, THIS, Lis pendens, Lead, READ, District court, NET, ARE, Summons, Counsel, Motion, Class Action, Action Replay, Therapy, Defendant, CLASS, Insurance

YOUR RIGHTS MAY BE AFFECTED BY THE PROPOSED SETTLEMENT OF A CLASS ACTION LAWSUIT PENDING IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA (THE "COURT").

Key Points: 
  • YOUR RIGHTS MAY BE AFFECTED BY THE PROPOSED SETTLEMENT OF A CLASS ACTION LAWSUIT PENDING IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA (THE "COURT").
  • PLEASE DO NOT CONTACT THE COURT, CORCEPT THERAPEUTICS INCORPORATED, OR ANY OTHER DEFENDANT, OR THEIR COUNSEL, REGARDING THIS NOTICE.
  • ALL QUESTIONS ABOUT THIS NOTICE, THE PROPOSED SETTLEMENT, OR YOUR ELIGIBILITY TO PARTICIPATE IN THE PROPOSED SETTLEMENT SHOULD BE DIRECTED TO LEAD COUNSEL OR THE CLAIMS ADMINISTRATOR, WHOSE CONTACT INFORMATION IS PROVIDED BELOW.
  • IF YOU ARE A MEMBER OF THE SETTLEMENT CLASS, YOUR RIGHTS MAY BE AFFECTED BY THE PROPOSED SETTLEMENT AND YOU MAY BE ENTITLED TO SHARE IN THE NET SETTLEMENT FUND.

O`KEY GROUP REPORTS 5.2% NET RETAIL REVENUE GROWTH, DA! DISCOUNTERS REVENUE GREW 22.1% IN Q4 2023

Retrieved on: 
Monday, February 5, 2024
AIX, KEY, Yoy, MOEX, RUB, DA, LFL, NET

Group net retail revenue [1] grew by 5.2% YoY to RUB 58.5 bn, driven by positive LFL performance of both O’KEY and DA!

Key Points: 
  • Group net retail revenue [1] grew by 5.2% YoY to RUB 58.5 bn, driven by positive LFL performance of both O’KEY and DA!
  • discounters' net retail revenue increased by 22.1% YoY to RUB 17.5 bn, led by both LFL net retail revenue growth and the chain’s expansion.
  • O`KEY hypermarkets’ net retail revenue decreased by 3.4% YoY to RUB 141.9 bn due to a decrease in LFL revenue and selling space.
  • discounters’ net retail revenue grew by 19.8% YoY to RUB 63.8 bn, led by LFL revenue and selling space growth.

InventHelp Inventor Develops New Mobile Software Application for Truck Drivers (CPC-739)

Retrieved on: 
Wednesday, January 31, 2024
Sale, Suite, Environment, NET

In doing so, it assists drivers with finding return loads in either local or long-haul cargo delivery service environments.

Key Points: 
  • In doing so, it assists drivers with finding return loads in either local or long-haul cargo delivery service environments.
  • As a result, it increases efficiency and it could allow for better and more affordable service to customers.
  • The invention features an effective design that is easy to use so it is ideal for the trucking industry and business owners.
  • 22-CPC-739, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Retrieved on: 
Friday, January 19, 2024
MSI, Patient, Pancreas, Cancer, Research, MSS, ASCO, Diagnosis, Lunch, Team Impulse, Society, TMB, TSC1, NET, Gastrointestinal tract, Liver, TSC2, Progress, Colorectal cancer, GI, Pharmaceutical industry

LOS ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA. 

Key Points: 
  • LOS ANGELES, Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    In a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers
    Most TSC1 and/or TSC2 inactivating alterations in liver and pancreatic cancers occurred in the context of low TMB and MSS tumors; whereas increased TMB and MSI signatures were enriched in colorectal cancer with TSC1 and/or TSC2 alterations
    Limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data.
  • More research is needed to understand the clinical and prognostic implications of these data
    Aadi is also presenting Trials-in-Progress (TiP) posters from its PRECISION 1 and NET clinical studies.
  • Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
    Title: "A phase 2, study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lunch, or pancreas"
    Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

NEVADA KING INTERSECTS HIGH-GRADE OXIDE GOLD 600M NORTH OF THE ATLANTA PIT WITH 9.72 G/T AU OVER 9.1M WITHIN 47.3M OF 2.57 G/T AU, DOUBLES SIZE OF THE "NORTH EXTENSION TARGET"

Retrieved on: 
Wednesday, January 17, 2024
NET, Gold, National instrument, Outline, Uranium mining

The 25 holes released today are plotted on eight separate cross sections together with 25 previously released Nevada King holes and 18 historical holes (Figures 3-10).

Key Points: 
  • The 25 holes released today are plotted on eight separate cross sections together with 25 previously released Nevada King holes and 18 historical holes (Figures 3-10).
  • Mineralization occurs along a gently west-dipping horizon developed at the contact between basal Ordovician age dolomite and overlying Tertiary age volcanics.
  • The east-directed vector is heading toward the still-to-be tested East Ridge Target, while the other vectors indicate potential to the west and south.
  • Today's drilling continues to outline this growing zone, which now covers a 330m x 350m size area, that is not included in the existing Atlanta resource.

Major Year of Launches, Crewed Space Flights from Florida's Space Coast

Retrieved on: 
Saturday, January 13, 2024
Columbia, International Space Station, ISS, Axiom Space, Starliner, TBD, Crew Dragon Freedom, Soyuz, Commercial Crew Program, Mission, Crew Dragon Endeavour, Sunita Williams, NET, COCOA, Boeing, NASA, EVA, Crew Dragon Resilience, Space Coast, Artemis 2, Kennedy Space Center, Extravehicular activity, SpaceX, Polaris Dawn, Certification, Communications satellite

That pace will continue this year, including plans for an impressive six crewed launches.

Key Points: 
  • That pace will continue this year, including plans for an impressive six crewed launches.
  • January 17 — Axiom Space began private, commercially crewed space flights in 2022, and this month will make their third mission to the International Space Station.
  • Axiom-3 features an all-European crew with chief astronaut Michael López-Alegría of Spain, who has flown on the space shuttle Columbia and a Soyuz craft.
  • Head to VisitSpaceCoast.com to begin planning your out-of-this-world vacation at the only beach that doubles as a launch pad.

Clearmind Medicine Completed Type A Meeting with the FDA

Retrieved on: 
Wednesday, January 10, 2024
MEAI, CWY, Serotonin, DAT, Reward, NET, IND, Food, Dopamine, FDA, Therapy, Norepinephrine, Pharmaceutical industry

"We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Key Points: 
  • "We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
  • The active ingredient in CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
  • MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b.
  • The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Retrieved on: 
Sunday, January 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Associate, Baylor College of Medicine, PKMYT1, BRCA, FDA, Breast, Progression-free survival, Society, Insilico Medicine, Cancer, Distinguishing, Translational research, Neck, PLK4, Workforce, Conference, Translation, Biology, IND, Colorectal cancer, MSN, NHT, University, PARP, Doctor of Philosophy, Calendar, District court, Harvard University, Immunotherapy, Food, Johnson & Johnson, NET, Huntsman Corporation, Cell adhesion, Therapy, TKI, USP1, Neoplasm, Experiment, Patient, NCI, Corporation, Baylor University, Huntsman Cancer Institute, Research, Acquisition, Dean (education), Education, Pnet, Head, Shareholder, Share repurchase, PFS, ADC, Pharmaceutical industry

The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.
  • Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.
  • In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.